Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
BNTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$79.88 - $131.49
Previous CloseN/A
Volume316.50K
Average Volume (3M)661.29K
Market Cap
$26.84B
Enterprise Value$9.88B
Total Cash (Recent Filing)$14.11B
Total Debt (Recent Filing)$293.00M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 03, 2025EPS Estimate
-1.17Last Dividend Ex-Date
Jun 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding240,398,730
10 Day Avg. Volume824,279
30 Day Avg. Volume661,292
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)1.36
Price to Sales (P/S)9.62
P/FCF Ratio-108.15
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue3.62
Enterprise Value/Gross Profit4.56
Enterprise Value/Ebitda-22.17
Forecast
1Y Price Target
$139.00Price Target Upside27.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBioNTech reported 2Q revenue well ahead of Street expectations, reaffirming full year guidance, indicating strong financial performance.
Oncology DevelopmentBioNTech's BNT327 is positioned to become a future backbone in treating PD-L1 resistant tumors, highlighting its potential impact in oncology.
Bears Say
COVID-19 Market DynamicsPotential risks with US booster adoption and evolving policy shifts could impact BioNTech's near-term COVID revenues.
Regulatory RisksThere is meaningful downside risk following Dr. Vinay Prasad’s exit at FDA’s Center for Biologics Evaluation and Research, especially if FDA manages to carve vaccine leadership out from the rest of CBER.
BioNTech SE News
BNTX FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was $79.88 and its highest was $131.49 in the past 12 months.
What is BioNTech SE’s market cap?
BioNTech SE’s market cap is $26.84B.
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Nov 03, 2025 which is in 82 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Aug 04, 2025. The company reported -$1.859 earnings per share for the quarter, beating the consensus estimate of -$2.653 by $0.794.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE pays a Notavailable dividend of $2.111 which represents an annual dividend yield of N/A. See more information on BioNTech SE dividends here
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is -1.17.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 240,398,730 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of -$1.859 in its last earnings report, beating expectations of -$2.653. Following the earnings report the stock price went up 2.506%.
Which hedge fund is a major shareholder of BioNTech SE?
Currently, no hedge funds are holding shares in BNTX
BioNTech SE Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$139.00 (27.22% Upside)
$139.00 (27.22% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 34.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $85.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.65%
12-Months-Change
Fundamentals
Return on Equity
-1.81%
Trailing 12-Months
Asset Growth
6.57%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE is a biotechnology company based in Germany that focuses on the development of personalized immunotherapies for cancer and other serious diseases. The company utilizes its proprietary mRNA technology platform to create innovative therapeutics and vaccines, including its widely known COVID-19 vaccine developed in partnership with Pfizer. BioNTech operates primarily in the biopharmaceutical sector, with a strong emphasis on personalized medicine and immune-oncology.
BNTX Company Deck
BNTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted BioNTech's strategic advancements and strong financial position, with significant partnerships and acquisitions enhancing their pipeline and capabilities. However, challenges remain, including a net loss, reduced COVID-19 vaccine uptake, and a missed trial endpoint in the melanoma study. While the company is making positive strides, the financial losses and COVID-19 challenges present notable hurdles.View all BNTX earnings summariesBNTX Stock 12 Month Forecast
Average Price Target
$139.00
▲(27.22% Upside)
Technical Analysis
Ownership Overview
0.42% Insiders
4.70% Mutual Funds
0.10% Other Institutional Investors
93.84% Public Companies and Individual Investors